Results 31 to 40 of about 229,451 (392)

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.

open access: yesNew England Journal of Medicine, 2019
BACKGROUND Apalutamide is an inhibitor of the ligand-binding domain of the androgen receptor. Whether the addition of apalutamide to androgen-deprivation therapy (ADT) would prolong radiographic progression-free survival and overall survival as compared ...
K. Chi   +19 more
semanticscholar   +1 more source

Effect of Lignocaine and a Topical Vapocoolant Spray on Pain Response during Surgical Castration of Beef Calves

open access: yesAnimals, 2019
This study assessed the efficacy of pre-operative injected lignocaine and peri-operative topical vapocoolant spray, administered as most practical for incorporation into routine calf castration procedures.
Dominique Van der Saag   +4 more
doaj   +1 more source

Effect of Castration on Some Physiological Aspect in Rats: Effect of Testosterone Hormone [PDF]

open access: yesمجلة التربية والعلم, 2010
This study provides novel information on the role of castration and testosterone hormone replacement at (5ng/kg B. Wt.) in rats in the parameters each of red blood corpuscles count, hemoglobin concentration, packed cell volume (PCV), erythrocytes indexes,
A. A. Hassan
doaj   +1 more source

Persistent neutrophil to lymphocyte ratio >3 during treatment with enzalutamide and clinical outcome in patients with castration-resistant prostate cancer [PDF]

open access: yes, 2016
The baseline value of neutrophil to lymphocyte ratio (NLR) has been found to be prognostic in patients with metastatic castration resistant prostate cancer (CRPC). We evaluated the impact of baseline NLR and its change in patients receiving enzalutamide.
Caffo, Orazio   +15 more
core   +3 more sources

Acute physiological responses to castration-related pain in piglets: the effect of two local anesthetics with or without meloxicam

open access: yesAnimal, 2016
Methods to reduce castration-related pain in piglets are still issues of concern and interest for authorities and producers. Our objectives were to estimate the effectiveness of two protocols of local anesthesia (lidocaine and the combination of ...
C. Bonastre   +6 more
doaj   +1 more source

Prevalence and risk factors for urinary incontinence in bitches five years after ovariohysterectomy [PDF]

open access: yesArquivo Brasileiro de Medicina Veterinária e Zootecnia, 2021
Ovariohysterectomy (OHE) is the most performed elective surgery in veterinary medicine. Although this procedure brings benefits both to the animal and public health, acquired urinary incontinence is a possible complication resultant from it.
B. Leupolt   +3 more
doaj   +2 more sources

Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer. [PDF]

open access: yes, 2016
Considerable evidence from both clinical and experimental studies suggests that androgen receptor variants, particularly androgen receptor variant 7 (AR-V7), are critical in the induction of resistance to enzalutamide and abiraterone.
Armstrong, Cameron   +4 more
core   +1 more source

Castration [PDF]

open access: yesJournal of Comparative Pathology and Therapeutics, 1892
n ...
openaire   +2 more sources

Efficacy and Safety of 4.7 mg Deslorelin Acetate Implants in Suppressing Oestrus Cycle in Prepubertal Female Dogs

open access: yesAnimals, 2022
Our multicentric, masked, controlled and randomised study aimed to assess the efficacy and safety of Suprelorin® 4.7 mg (Virbac, Carros, France) regarding oestrus prevention in prepubertal intact bitches.
Aymeric Gontier   +6 more
doaj   +1 more source

Darolutamide in Nonmetastatic, Castration‐Resistant Prostate Cancer

open access: yesNew England Journal of Medicine, 2019
BACKGROUND Darolutamide is a structurally unique androgen‐receptor antagonist that is under development for the treatment of prostate cancer. We evaluated the efficacy of darolutamide for delaying metastasis and death in men with nonmetastatic ...
K. Fizazi   +13 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy